Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations
    • TOBACCO—Ala. Sup. Ct.: Preliminary injunction denied where challenge to ENDS Act failed to demonstrate likelihood of success
    • DRUGS AND BIOLOGICS—NOTICES: FDA withdraws approval for multiple NDAs
    • ELECTRONIC HEALTH RECORDS—M.D. Fla.: Suit against physical therapy clinic franchisor over data breach can proceed
    • GENERAL HEALTH CARE NEWS—NOTICES: AHRQ announces voluntary delisting of a PSO
    • HOSPICE—PRRB DECISIONS: Hospice quality reporting requirements make internal submission errors noncompliant with FY 2024 payment update standards
    • MEDICAID—D. Md.: FCA rebate stacking case proceeds to discovery despite Allergan Sales’s motion to reconsider dismissal
    • PRESCRIPTION DRUGS—8th Cir.: Denial of preliminary relief affirmed in Novartis challenge to Missouri 340B drug delivery law
    • QUALITY OF CARE—PRRB DECISIONS: Medicare quality reporting requirements mandate timely data submission, limited availability of exceptions for missed hospital IQR deadlines
    • VITAL BRIEFING—Planned Parenthood’s Medicaid funding resumes
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations

    Health Law Daily Wrap Up, DRUGS AND BIOLOGICS—NOTICES: FDA withdraws approval for multiple NDAs, (Jul 9, 2026)

    By WK Editorial Staff

    The FDA is withdrawing approval of 34 new drug applications (NDAs) from multiple applicants.

    The applicants notified the FDA in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. Ap ...

    By WK Editorial Staff

    The FDA is withdrawing approval of 34 new drug applications (NDAs) from multiple applicants.

    The applicants notified the FDA in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. Approval of each entire application is withdrawn, including any strengths and dosage forms included in the application (Notice, 91 Fed. Reg. 41045 (July 6, 2026)).

    Dates. Approval is withdrawn as of August 5, 2026.

    FederalRegisterIssuances: Notices FDCActNews DrugBiologicNews

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use